explore -WSS

explore

author：fashion 2025-09-28 02:31:51 - browse：57939

Adam's take main illustration — Molly Ferguson/STAT

Hello! Some takes and thoughts on Gilead’s Trodelvy troubles, Elevation Oncology’s surprising rise, and Kura Oncology’s “wall-crossing” stock sale.

Gilead needs Arcellx more than ever

The clinical trial setback for Trodelvy in non-small cell lung cancer reported by Gilead Sciences on Monday was another dose of bad news for the company’s oncology business. Strategically, does it make sense for Gilead to invest even more in antibody-drug conjugates like Trodelvy, where its lackluster profile and increased competition overall makes winning seem unlikely? Or, should Gilead double down on its Kite division and CAR-T cell therapy — the type of cancer treatments where it truly excels?

If the answers to those questions are no and yes (I lean that way), then Gilead’s current partnership with Arcellx, which is developing a BCMA-targeted CAR-T therapy for multiple myeloma, becomes a lot more important.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： The biotech scorecard for Q3: 15 stock

focus

WSS

Prescription digital therapeutics are key to pharma’s future

How Robert F. Kennedy Jr. distorted vaccine science

AstraZeneca lung cancer study comes in below expectations

Lupron, used to halt puberty in children, may cause lasting health problems

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

Canadians with cystic fibrosis outlive Americans by a decade

focus

explore

Gilead needs Arcellx more than ever

knowledge

BioMarin wins approval for gene therapy to treat hemophilia A

Being 'nonadherent' patient made me a more empathetic doctor

Wildfire smoke exposes gaps in outdoor worker protections

Canadians with cystic fibrosis outlive Americans by a decade

Hepatitis C has a cure — but many Americans still lack access to it

Drug cartel violence flares in western Mexico after vigilante leader's killing

Anesthesiologist group: stop taking Ozempic before surgery

STAT wants to know your pick for a great summer read or listen

Duchenne breakthrough therapy leaves behind pioneering families

Being 'nonadherent' patient made me a more empathetic doctor

hotspot

UpToDate has a racism problem: Dr. Stanley Goldfarb

Canadians with cystic fibrosis outlive Americans by a decade

A letter from the executive editor: The 2023 STATUS List

Being 'nonadherent' patient made me a more empathetic doctor

Use doctors trained outside the U.S. to ease the physician shortage

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

hotspot

focus

knowledge

focus